60 Degrees Pharmaceuticals, Inc. (SXTP)

The company implemented a one-for-four reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. A partnership with Runway Health was announced to expand access to Arakoda for international travelers, leading to a stock price surge. Q3 2025 financial results highlighted increased revenue but also ongoing losses and higher operating expenses, including a gross loss due to a one-time inventory write-off. The company announced the detection of Babesia infection in 24% of patients with chronic fatigue, supporting the continuation of its B-FREE study for chronic babesiosis, and opened the B-FREE Phase 2 site at Mount Sinai. The first patient in its relapsing babesiosis study tested negative for infection, and a Breakthrough Therapy Designation request was submitted to the FDA but later declined. Q2 2025 financial results showed a 19% year-over-year decrease in net product revenues due to a temporary supply disruption of Arakoda 16-count boxes, but profitability increased due to higher usage of a cash-pay distribution model and the importation of Kodatef. Insiders have shown buying activity, including purchases by CEO Geoffrey Dow.

Demand for 60 Degrees Pharmaceuticals, Inc.'s products and services exhibits seasonality, particularly for Arakoda, influenced by global travel patterns and peak travel seasons to malaria-endemic regions. The company's focus on tick-borne illnesses like babesiosis suggests another layer of seasonality, with babesiosis incidence typically higher during tick seasons, correlating with increased demand for related diagnostic and treatment options.

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for infectious diseases, operating within the Biotechnology industry. The company addresses unmet medical needs in vector-borne diseases through small-molecule therapeutics, with its flagship product, Arakoda (tafenoquine), being an FDA-approved medication for malaria prevention. The company's pipeline includes development programs for other infectious diseases, such as COVID-19, babesiosis, fungal pneumonias, candidiasis, Zika, respiratory viruses, and dengue. They are also exploring potential in-licensing for a Lyme disease product and an antimalarial combination partner for P. vivax malaria.

Headquartered in Washington, D.C., 60 Degrees Pharmaceuticals, Inc. has a subsidiary in Australia. Its primary commercial product, Arakoda, is available in both the U.S. and Australia. The company also collaborates with research and academic organizations in both countries.

60 Degrees Pharmaceuticals, Inc. maintains a positive professional image within its niche, recognized for developing "lifesaving medicines" and achieving FDA approval for Arakoda. Ongoing clinical trials and positive early data contribute to a reputation of scientific advancement and addressing unmet medical needs. The partnership with Runway Health reflects a proactive approach to market penetration and patient care. No explicitly negative reputation-impacting events beyond financial performance fluctuations have been reported.

60 Degrees Pharmaceuticals, Inc. has 13 institutional owners and shareholders holding a total of 42,712 shares. Major institutional owners include DRW Securities, LLC, Geode Capital Management, Llc, Tower Research Capital LLC (TRC), UBS Group AG, Citigroup Inc, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Advisor Group Holdings, Inc., Bank Of America Corp /de/, Heights Capital Management, Inc., Orca Capital GmbH, Armistice Capital LLC, Knight Therapeutics Inc., Osaic Wealth, Inc., and The Vanguard Group, Inc. Individual insiders hold 1.69% of the stock, while institutions hold 7.96%. Geoffrey Dow, the CEO and Chairman, is a notable individual owner and has recently increased his holdings.